Lilly’s second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street estimates.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.
Staffing shortages, rising prescription drug use, and costly new therapies have driven inflation in the medical sector.
“We’re pushing the boundaries of the size of the problems we can look at with quantum.”
Weight Watchers went bankrupt in May, but now it promises it’s trimmed the fat off its books and is ready to rejoin the Nasdaq.
This patent isn’t the first time we’ve seen AI make inroads into healthcare.
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.
Novo and Hims’ April team-up turned the two firms from competitors into collaborators at just the right moment.
The US and New Zealand are the only two countries that allow pharmaceutical companies to directly advertise to patients on TV.
Cyber-criminals often see healthcare firms’ shoddy protection as a “pot of gold.”
At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.
While virtual care boomed during the pandemic, the sector more recently had an up-and-down couple of years as the world returned to normalcy.
Moderna is counting on revenue from newer mRNA vaccines, including a next generation Covid shot, to make up for falling sales.
UnitedHealth Group has called in its CEO to deal with a Medicare Advantage program that’s crunching margins.
The Trump administration promised to drastically cut prescription drugs prices in the US, where the industry makes most of its money.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.